Digest Network Come funziona
Network
/
Società
Bi
Non verificato

Biogen Inc.

Di cosa scriviamo

Annunci EconomiciBiotecnologiaFinanzaManagement/Organizzazione AziendaleMedicina Salute Benessere

70 comunicati stampa

Guarda tutti i comunicati
15/07/2026
Biotecnologia
Biogen Appoints Michael J. Parini as Chief Legal Officer
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
29/06/2026
Biotecnologia
Medicina Salute Benessere
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
17/06/2026
Biotecnologia
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
04/06/2026
Biotecnologia
Annunci Economici
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
03/06/2026
Biotecnologia
Medicina Salute Benessere
Annunci Economici
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
14/05/2026
Biotecnologia
Medicina Salute Benessere
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
20/04/2026
Biotecnologia
Management/Organizzazione Aziendale
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
31/03/2026
Biotecnologia
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
30/03/2026
Biotecnologia
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
28/03/2026
Biotecnologia
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0